INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Neos Thera...
October 07 2016 - 4:14PM
Business Wire
Levi & Korsinsky, LLP announces that it has commenced an
investigation of Neos Therapeutics, Inc. (“Neos Therapeutics” or
the “Company”) (NASDAQGM:NEOS) concerning possible violations of
federal securities laws by the Company and/or certain of its
officers and directors.
On October 19, 2015, Neos Therapeutics disclosed that the U.S.
Food and Drug Administration has identified deficiencies in the
Company’s new drug application for Cotempla XR-ODT that preclude
discussion of labeling and marketing requirements at this time.
Shares of Neos Therapeutics were down more than 23% on intraday
trading on October 20, 2015. Then on August 11, 2016, Neos
announced its financial results for the second quarter of 2016,
reporting it had missed its earnings expectations by a significant
$0.49 per share. Following this news, shares of Neos fell from a
close of $8.57 per share on August 10, 2016 to a close of $7.27 per
share on August 11, 2016. To obtain additional information about
the investigation, go to:
http://zlk.9nl.com/neos-therapeutics-neos
or contact Joseph E. Levi, Esq. either via email at
jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877)
363-5972.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits.
Attorney advertising. Prior results do not guarantee similar
outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161007005787/en/
Levi & Korsinsky, LLPJoseph E. Levi, Esq.Tel:
212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2023 to Apr 2024